Epidermal Growth Factor 2 Negative Carcinoma of Breast clinical trials at UCSF

1 research study open to eligible people

Epidermal growth factor 2 negative carcinoma of the breast is a type of breast cancer that does not have high levels of a protein called HER2. UCSF is recruiting for a study evaluating the safety and effects of a new drug for adults with advanced solid tumors. This trial helps understand how the drug works in the body.

Showing trials for

  • NKT3447 for Adults with Advanced/Metastatic Solid Tumors

    open to eligible people ages 18 years and up

    The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of NKT3447 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and the preliminary antitumor activity of NKT3447 in adult subjects with cyclin E1 (CCNE1) amplified ovarian cancer at the RDEs selected in Dose Escalation and to determine the preliminary recommended phase 2 dose (RP2D).

    San Francisco, California and other locations

Last updated: